Author: CV Herst; S Burkholz; J Sidney; A Sette; PE Harris; S Massey; T Brasel; E Cunha-Neto; DS Rosa; WCH Chao; R Carback; T Hodge; L Wang; S Ciotlos; P Lloyd; R Rubsamen
Title: An Effective CTL Peptide Vaccine for Ebola Zaire Based on Survivors’ CD8+ Targeting of a Particular Nucleocapsid Protein Epitope with Potential Implications for COVID-19 Vaccine Design Document date: 2020_2_27
ID: i55tm3hh_7
Snippet: ELISPOT. That study also demonstrated that the microencapsulated peptides alone were insufficient to induce an adequate immune response without the presence of the TLR-4 and TLR-9 agonists administered as described. The TLR agonists used for this vaccine formulation are used in FDA approved vaccines 75 and can be sourced as non-GMP or GMP material for pre-clinical and clinical studies......
Document: ELISPOT. That study also demonstrated that the microencapsulated peptides alone were insufficient to induce an adequate immune response without the presence of the TLR-4 and TLR-9 agonists administered as described. The TLR agonists used for this vaccine formulation are used in FDA approved vaccines 75 and can be sourced as non-GMP or GMP material for pre-clinical and clinical studies.
Search related documents:
Co phrase search for related documents- adequate immune response induce and immune response: 1, 2, 3
- clinical pre clinical study and immune response: 1
- immune response and TLR agonist: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- immune response and vaccine formulation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- TLR agonist and vaccine formulation: 1
- TLR agonist and vaccine formulation TLR agonist: 1
Co phrase search for related documents, hyperlinks ordered by date